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Abstract
Allergen specific immunotherapy (SIT) is the practice of administering gradually increasing doses of
the specific causative allergen to reduce the clinical reactivity of allergic subjects, and is the only
treatment targeting the causes of hypersensitivity and not only the symptoms, as done by drugs.
The traditional, subcutaneous immunotherapy (SCIT) was burdened by the problem of systemic
reactions which may be sometimes severe and - though very rarely - even fatal. This was the
background to develop non injections routes for SIT and particularly sublingual immunotherapy
(SLIT), that emerged as a real treatment option for respiratory allergy.
A number of studies was conducted to evaluate efficacy and safety of SLIT, the first meta-analysis
- including 22 placebo-controlled trials - concluded for positive results in both issues, but the
number of studies on children was too low to draw definite conclusions. Since then, many other
studies became available and make possible to analyze SLIT in children in its well defined aspects as
well as in sides still requiring more solid data.
Introduction
Allergen specific immunotherapy (SIT) is the practice of
administering gradually increasing doses of the specific
causative allergen to reduce the clinical reactivity of aller-
gic subjects, and is the only treatment targeting the causes
of hypersensitivity and not only the symptoms, as done by
drugs [1]. The traditional, subcutaneous immunotherapy
(SCIT) was burdened by the problem of systemic reac-
tions which may be sometimes severe and - though very
rarely - even fatal [2]. This was the background to develop
non injections routes for SIT and particularly sublingual
immunotherapy (SLIT), that emerged as a real treatment
option for respiratory allergy [3].
A number of studies was conducted to evaluate efficacy
and safety of SLIT, the first meta-analysis - including 22
placebo-controlled trials - concluded for positive results
in both issues, but the number of studies on children was
too low to draw definite conclusions [4]. Since then,
many other studies became available and make possible
to analyze SLIT in children in its well defined aspects as
well as in sides still requiring more solid data.
Efficacy of Slit in Children
The clinically efficacy of SLIT, as of SIT in general, is eval-
uated by the decrease in symptom scores of rhinitis and
asthma and in consumption of symptomatic drugs. Many
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placebo-controlled studies are conducted on small patient
populations and cannot achieve a reliable statistical sig-
nificance, but their combined evaluation by the tool of
meta-analysis is considered an adequate method to obtain
more robust data [5]. The results obtained by the
Cochrane Collaboration method [6] are expressed as
standardized mean difference (SMD) and allow to com-
pare the effect of SLIT on actively and placebo treated
patients. Also systematic reviews, that is, literature analy-
sis without using the Cochrane method, are available.
The progressive increase in number of SLIT studies
addressing the pediatric population made possible to per-
form specific meta-analyses and systematic reviews. The
first systematic review included the studies up to June
2003, which were evaluated qualitatively, and concluded
for low to moderate efficacy of SLIT only in children with
house dust mite induced mild to moderate asthma [7]. A
meta-analysis by Olaguibel et al including 7 randomized
controlled studies conducted on children aged up to 14
years was substantially in agreement, since it found that
SLIT was significantly effective on asthma symptoms
(SMD -1.42, p = 0.01) and on drug consumption (SMD -
1.01, p = 0.06), while the improvement did not reach the
significance for nasal and conjunctival symptoms [8].
A further meta-analysis on SLIT in children was published
in 2006 [9]: in this case the evaluation concerned the effi-
cacy on allergic rhinitis including 10 randomized control-
led studies, with an overall number of 484 patients (245
actively and 239 placebo treated). A significant reduction
of both symptoms (SMD - 0.56, p = 0.02) and medication
(- 0.76, p = 0.03) was observed. A notable aspect was pro-
vided from the sub-analysis addressing the length of treat-
ment and the kind of allergen administered, which
demonstrated a higher efficacy for durations longer than
18 months and for pollen allergens compared to house
dust mites.
The same group performed a meta-analysis on the efficacy
of SLIT in allergic asthma, analyzing 9 studies on pediatric
patients which included a total number of 441 patients,
232 actively treated and 209 placebo-treated [10]. A sig-
nificant reduction was found in both symptoms scores
(SMD - 1.14, p = 0.02) and drug use (SMD -1.63, p =
0.007).
A systematic review in the same year by Roder et al evalu-
ating any form of immunotherapy in children concluded
for no evidence of effectiveness in the subgroup of 11
studies on SLIT, but the review was based on analysis of
each single study and not on pooling all data together
[11]. The authors justified such approach with the rele-
vant heterogeneity of the available studies.
Actually, heterogeneity, which is mainly due to different
scoring systems in the various studies. is a limit of meta-
analysis. However, a data source alternative to meta-anal-
ysis are studies conducted on large numbers of patients
that provide adequate statistical power. The recent prepa-
rations for SLIT in orosoluble tablet of grass pollen extract
were evaluated on large populations, including 253 chil-
dren treated by a one grass (Phleum pratense) extract [12],
and 278 children treated with a 5-grass pollen extract [13].
These studies showed a highly significant improvement in
symptom and rescue medications scores in actively
treated compared with placebo treated patients during the
grass pollen season. Thus, the criticism on the efficacy of
SLIT in children does not seem to have ground. An
updated and balanced review on this issue by Larenas-Lin-
nemann was recently published [14]. The author after
accurate analysis of all the available studies concluded
that "evidence of effect is confirmed for SLIT in children
with allergic rhinitis or asthma caused by pollen expo-
sure", while there is yet room for investigations on long-
term effects and preventive action of SLIT, as well as on
optimal dosing for dust mites. Indeed, the dosing is a piv-
otal factor, and the dose-dependence of efficacy in chil-
dren treated with pollen extract was clearly demonstrated
both clinically [15] and immunologically [16]. Dose-
response studies in mite allergic children are warranted.
Another important observation concerns the capacity of
SLIT to prevent the development of asthma in children
with seasonal rhinitis treated with grass pollen extract
compared with subjects treated with standard sympto-
matic drugs [17].
Safety of Slit in Children
All systematic revisions and meta-analysis found that the
most common adverse events to SLIT, regardless the age,
are local reactions in the oropharynx - with itching, tin-
gling and swelling in the mouth - followed by local gas-
trointestinal reactions - with nausea, vomiting or diarrhea
- and that systemic reactions such as asthma, rhinitis, or
urticaria, are quite rare [4,18-20]. An increased risk of sys-
temic reactions is apparent in subjects undergoing SLIT
because of previous systemic reactions to SCIT [21,22]. In
particular, one of the cases of anaphylaxis concerned a
pediatric patient, who had had urticaria to previous SCIT
treatment and developed an anaphylactic reaction after
the very first dose of a grass pollen tablet formulation with
no updosing phase [21].
Some studies addressed specific safety issues in children.
SLIT was well tolerated using ultra-rush schedules - that
reach the maintenance dose in a few hours [23] - and also
starting the treatment during the pollen season [24]. Two
studies demonstrated that SLIT is safe also in children
younger than 5 years (that is the age limit indicated for
SCIT), as assessed by comparable rate and kind of adverseItalian Journal of Pediatrics 2009, 35:31 http://www.ijponline.net/content/35/1/31
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effects in patients aged less or more than 5 years [25,26].
A further observation regarded children treated with one
or multiple allergen extracts, who showed comparable
rates of side effects, more than 90% being mild and self-
resolving [27].
Concerning SLIT with house dust mites extracts, a recent
study (including both adults and children) reported a
comparable safety and tolerability in patients treated con-
tinuously or intermittently, i.e. 2-month treatment alter-
nate to-2 month suspension [28].
Issues Influencing the Feasibility of Slit
As stated above, SLIT has clear evidence of efficacy and
safety. Still, there are aspects influencing its clinical
results, such as the compliance, or its prescription, such as
the cost-effectiveness.
Compliance to SLIT
According to established definitions, compliance is "The
extent to which a patient's behavior matches the pre-
scriber's advice" and adherence is "The extent to which the
patient's behavior matches agreed recommendations
from the prescriber" [29], and both of the are essential for
the clinical outcome of a medical treatment. A number of
studies conducted on SCIT showed that the major cause of
noncompliance was the inconvenience, related to injec-
tions and particularly to their frequency, and the cost of
the treatment [30]. SLIT has different compliance issues
than SCIT, because it is administered at home by patients
themselves and thus it is not affected by most causes
reported for non-compliance to allergen injections, hav-
ing instead compliance problems similar to drug treat-
ment. Some studies not specifically designed for
compliance (for instance safety and tolerability analyses)
reported that treatment withdrawal is frequently caused
by repeated local reactions in the mouth or at gastrointes-
tinal level [4,18]. Concerning specific compliance and
adherence studies, the available data indicate quite satis-
factory results.
In a study on children treated with SLIT by an allergen
extract in monodoses, parents were interviewed by
unscheduled phone calls at the third and sixth month of
SLIT and asked to count at once the remaining doses; a
compliance rate higher than 75% was found in 85% of
children at the third month and in 84% of children at the
sixth month; the major cause of withdrawal (5.6% of
cases) was the cost of treatment, while side effects
accounted for 1.4% of stopping [31]. In a study compar-
ing compliance to SLIT, SCIT and local nasal immuno-
therapy in children, data on SLIT concerned 806 patients,
173 of whom (21.4%) were noncompliant, with a highly
significant difference (p < 0.0001) for a better compliance
in hospital setting (90.5%) compared to private office set-
ting (61.2%); the most common reason of withdrawal
was the cost of treatment, reported globally in 36.4% of
cases, followed by inconvenience, feeling of inefficacy,
and side effects [32].
Cost-effectiveness of SLIT
Many studies are available, recently reviewed, showing
that SLIT provides economic advantage compared with
drug treatment by bringing a better clinical outcome at a
reduced cost or an extra benefit at a very acceptable extra
cost [33]. Concerning children, fhe first published study
dealt with the evaluation of cost effectiveness of SLIT, with
the high dose suggested in the ARIA document [34], in
subjects with allergic rhinitis and asthma. From records of
pediatric patients seen for respiratory allergy, who had 1-
year data prior to receive SLIT and 3-year data on high
dose SLIT, outcome measures (the number of exacerba-
tions, visits, absence from nursery or school) were ana-
lyzed. Moreover, direct costs (Euro spent on drugs,
specialists visits, and SLIT) and indirect costs (costs result-
ing from children school and parental work loss) were
considered. A second analysis compared a sub-group of
children with allergic asthma, using a control group for
costs, based on records of patients not treated with SLIT,
extracted from a network-database of pediatricians. An
overall number of 135 children were analyzed, 46 with
perennial and 89 with seasonal allergy, with comparable
gender and age distribution. A substantial reduction was
found in all outcome measures during SLIT compared
with the previous period. The average annual cost/patient
was Euro 2672 before SLIT initiation and Euro 629/year
during SLIT. Similar results were found for allergen sub-
groups. The asthma analysis involved 41 children with
SLIT and 35 controls, and also showed a substantial
reduction in outcomes, though the direct cost per patient
over the 4 years follow-up was € 1182 for SLIT-treated
children and € 1100 for controls [35]. A study conducted
in France estimated that in children treated with SLIT for
house dust mite or pollen allergies, the incremental costs
per asthma case avoided over a 7-year period, compared
with standard symptomatic treatment, were 3938 Euro for
dust mite and 824 Euro for pollen allergy; of note, there
was an economic advantage of SLIT also versus SCIT for
pollen allergy, since the incremental cost for the latter was
1708 Euro [36].
Conclusion
SLIT was successfully introduced in Europe mainly on
safety grounds and in some countries, including Italy, is
currently more frequently employed than SCIT. The anal-
ysis of the abundant literature supports the use of SLIT in
children with rhinitis and asthma caused by sensitization
to seasonal allergens, while further studies are needed to
demonstrate a full effectiveness in sensitization to peren-
nial allergens. Favourable data obtained from studies onItalian Journal of Pediatrics 2009, 35:31 http://www.ijponline.net/content/35/1/31
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compliance and cost-effectiveness make SLIT a feasible
treatment for treatment with respiratory allergy.
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